Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not？

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• Immune-checkpoint inhibitors are transforming cancer treatment.
• Lack of predictive biomarkers limits immunotherapy application in some patients.
• Gut commensal bacteria are increasingly recognized for their role in modulating treatment efficacy.

Purpose of the Study:

• To review the impact of gut commensal bacteria on the tumor immune microenvironment.
• To highlight specific bacteria associated with immune-checkpoint inhibitor therapy.
• To discuss the predictive value of gut microbiota composition for immunotherapy outcomes.

Main Methods:

• Literature review of studies investigating the gut microbiome and cancer immunotherapy.
• Analysis of existing data on bacterial species and their correlation with treatment response.
• Synthesis of findings on the mechanisms by which gut bacteria influence the tumor immune milieu.

Main Results:

• Gut commensal bacteria composition significantly affects the efficacy of immune-checkpoint inhibitors.
• Specific bacterial species have been associated with improved or diminished responses to immunotherapy.
• Microbiome analysis can help predict patient response and potential toxicity of cancer immunotherapy.

Conclusions:

• Gut commensal bacteria play a crucial role in the efficacy of immune-checkpoint inhibitors.
• Targeting or modulating the gut microbiome may enhance cancer immunotherapy outcomes.
• Microbiome profiling represents a promising avenue for developing predictive biomarkers for immunotherapy.